Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases

Fig. 4

Role of transcriptional co-activators in lung cancer, head and neck cancer and leukemia. (a) In lung cancer, non-small cell lung cancer (NSCLC) growth is facilitated by the activity of several transcriptional co-activators including CRTC2, CBP/p300, PC4 and MRTF. The transcriptional co-activator COLCA1 interacts with the transcription factor POU2F3 to promote small cell lung cancer (SCLC) growth. (b) In head and neck cancers (HNC), YAP and AIB1 interact with TEAD family of transcription factors to facilitate tumorigenesis. TAZ, on the other hand, forms a complex with TEAD4, binds to the promoter region of the pluripotency gene SOX2, consequentially initiating its transcription, thereby upregulating self-renewal and maintenance of CSC population. The co-activator molecules CRTC2, TRIM24 and BRD4 have also been reported to be actively involved in head and neck cancer growth, proliferation and CSC maintenance. (c) In leukemia, deregulation of the co-activators MKL/MRTF-A, CBP/p300, CITED2, BRD4 and DDX5 have been observed. CSC, cancer stem cells; AMKL, acute megakaryoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; ALL, acute lymphocytic leukemia. This figure was created using BioRender (https://biorender.com/)

Back to article page